The CHMP recommends Tecvayli for second-line treatment of relapsed or refractory multiple myeloma. Explore the EU ...

Aethlon Medical agrees to merge with North Immunology to advance NOR-101, a bispecific antibody targeting atopic dermatitis. Read more now for investors.

The AllSci BriefFree, systematic R&D and deal news. Daily. Airway Therapeutics, Inc. has received a USD 1.9 million NHLBI R44 SBIR grant to fund a Phase IIb/III trial of zelpultide alfa, a recombinant ...

SKY-0515 delivered a statistically significant 1.59-point cUHDRS advantage in Huntington’s disease—see what it means.

MasterSwitch won a $1.19M NIDDK SBIR grant to advance cirrhosis therapy. Read how the award supports IND-enabling studies and liver disease treatment.

The FDA updated Ibtrozi’s label to show a 49.7-month response duration in TKI-naive ROS1-positive lung cancer. See what changed.

Matisse Pharmaceuticals has raised €14 million to advance isupartob sodium into a Phase II sepsis trial. Read the latest ...

Orbis Medicines partners with Novo Nordisk on oral cardiometabolic drug discovery in a deal worth up to $1.4 billion. Read ...

GOA Therapeutics unveils GOA26, a first-in-class IV treatment for acute alcohol poisoning, backed by $15.5 million. Read the latest details.

Penn researchers reveal how the NSD2–SETD2–EZH2 axis drives immune evasion in KRAS-driven lung cancer. Explore the Nature Communications findings now.

Sling Therapeutics has begun its global Phase III ORBIT trial of oral linsitinib for thyroid eye disease. Read the latest ...

Acelot has dosed the first volunteer in a Phase Ia trial of ACE-2223, an oral TDP-43 drug for ALS. Explore the trial, science ...